179 related articles for article (PubMed ID: 34213454)
1. Metreleptin replacement treatment improves quality of life and psychological well-being in congenital generalized lipodystrophy.
Simsir IY; Yurekli BS; Polat I; Saygili F; Akinci B
Natl Med J India; 2020; 33(5):278-280. PubMed ID: 34213454
[TBL] [Abstract][Full Text] [Related]
2. Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the
Özalkak Ş; Demiral M; Ünal E; Taş FF; Onay H; Demirbilek H; Özbek MN
J Clin Res Pediatr Endocrinol; 2023 Aug; 15(3):329-333. PubMed ID: 35735786
[TBL] [Abstract][Full Text] [Related]
3. Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution.
Adiyaman SC; V Schnurbein J; De Laffolie J; Hahn A; Siebert R; Wabitsch M; Kamrath C
J Pediatr Endocrinol Metab; 2022 Jul; 35(7):946-952. PubMed ID: 35405042
[TBL] [Abstract][Full Text] [Related]
4. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
[TBL] [Abstract][Full Text] [Related]
5. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.
Christensen JD; Lungu AO; Cochran E; Collins MT; Gafni RI; Reynolds JC; Rother KI; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1493-500. PubMed ID: 25070319
[TBL] [Abstract][Full Text] [Related]
7. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
Tchang BG; Shukla AP; Aronne LJ
Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
[TBL] [Abstract][Full Text] [Related]
8. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
9. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
Fukaishi T; Minami I; Masuda S; Miyachi Y; Tsujimoto K; Izumiyama H; Hashimoto K; Yoshida M; Takahashi S; Kashimada K; Morio T; Kosaki K; Maezawa Y; Yokote K; Yoshimoto T; Yamada T
Endocr J; 2020 Feb; 67(2):211-218. PubMed ID: 31708526
[TBL] [Abstract][Full Text] [Related]
10. W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?
Mantzoros CS
Endocr Pract; 2010; 16(2):162-6. PubMed ID: 20350904
[No Abstract] [Full Text] [Related]
11. Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
Patni N; Garg A
Nat Rev Endocrinol; 2015 Sep; 11(9):522-34. PubMed ID: 26239609
[TBL] [Abstract][Full Text] [Related]
12. Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy.
Muniyappa R; Abel BS; Asthana A; Walter MF; Cochran EK; Remaley AT; Skarulis MC; Gorden P; Brown RJ
J Clin Lipidol; 2017; 11(2):543-550. PubMed ID: 28502512
[TBL] [Abstract][Full Text] [Related]
13. Treatment Options for Lipodystrophy in Children.
Mainieri F; Tagi VM; Chiarelli F
Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
[TBL] [Abstract][Full Text] [Related]
15. First metreleptin treatment for generalized lipodystrophy in Turkey.
Simsir IY; Yurekli BS; Saygili F; Altay C; Akinci B
Diabetes Obes Metab; 2017 Feb; 19(2):299-301. PubMed ID: 27717125
[No Abstract] [Full Text] [Related]
16. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
[TBL] [Abstract][Full Text] [Related]
17. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
Akinci G; Akinci B
Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
[TBL] [Abstract][Full Text] [Related]
18. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
[TBL] [Abstract][Full Text] [Related]
19. Metreleptin Treatment in Three Patients with Generalized Lipodystrophy.
Musso C; Major ML; Andres E; Simha V
Clin Med Insights Case Rep; 2016; 9():123-127. PubMed ID: 28096701
[TBL] [Abstract][Full Text] [Related]
20. Update on Therapeutic Options in Lipodystrophy.
Akinci B; Meral R; Oral EA
Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
